The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The Lancet Diabetes and Endocrinology

• Publication date

  2015-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S2213-8587(15)00261-2PMID 26268910
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Functional Interaction between Angiotensin II Receptor Type 1 and Chemokine (C-C Motif) Receptor 2 with Implications for Chronic Kidney Disease

  2015cited by this paper
• Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.

  2015cited by this paper
• Combined angiotensin inhibition for the treatment of diabetic nephropathy.

  2013cited by this paper
• Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice.

  2013cited by this paper
• CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice.

  2013cited by this paper
• Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

  2012cited by this paper
• Orally-Administered Chemokine Receptor CCR2 Antagonist CCX140-B in Type 2 Diabetes: A Pilot Double-Blind, Randomized Clinical Trial

  2012cited by this paper
• Proteinuria should be used as a surrogate in CKD

  2012cited by this paper
• Changes in albuminuria predict mortality and morbidity in patients with vascular disease.

  2011cited by this paper
• The kidney in type 2 diabetes therapy.

  2011cited by this paper
• An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.

  2011cited by this paper
• Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes.

  2008cited by this paper
• MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy.

  2008cited by this paper
• MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity.

  2006cited by this paper
• Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.

  2005cited by this paper
• Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

  2004cited by this paper
• Monocyte chemoattractant protein 1 in obesity and insulin resistance

  2003cited by this paper
• Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails.

  1994cited by this paper
• Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

  1975cited by this paper

• The Pathological Role of LDL in Membranous Nephropathy and Diabetic Nephropathy and the Protective Efficacy of LDL Apheresis: A Narrative Review

  2026cites this paper
• Modulation of CCR2/CCL2 molecular axis in the expansion and rupture of abdominal aortic aneurysms.

  2026cites this paper
• Inflammation and Diabetic Kidney Disease

  2026cites this paper
• Inhibition of IL-33 in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Phase 2b Trial.

  2025cites this paper
• Mechanisms of diabetic kidney disease and established and emerging treatments

  2025cites this paper
• Targeting NF-κB in diabetic nephropathy: exploring the therapeutic potential of phytoconstituents

  2025cites this paper
• Mechanism exploration of Wenshen Jianpi Decoction on renoprotection in diabetic nephropathy via transcriptomics and metabolomics.

  2025cites this paper
• The Dual Role and Therapeutic Implications of the Wnt/β-Catenin Pathway in Diabetic Kidney Disease

  2025cites this paper
• Navigating the Complex Pathogenesis of Acute Kidney Injury: Exploring Macrophage Dynamics, Mitochondrial Dysfunction, and Ferroptosis Pathways.

  2025cites this paper
• Chemokine–receptor-guided B-cell immunity in cardiovascular disease

  2025cites this paper
• Macrophages in Focus: Key Drivers and Therapeutic Opportunities in Diabetic Kidney Disease

  2025cites this paper
• Proteomics of Urinary Extracellular Vesicles Highlight the Involvement of Vitronectin and the Fibrinolytic and TNF Pathways as Mechanisms Underlying Renal Fibrosis in Kidney Transplant Patients

  2025cites this paper
• Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomized control trials

  2025cites this paper
• Progress in structure-based drug development targeting chemokine receptors

  2025cites this paper
• Innate immune cells in acute and chronic kidney disease

  2025influential citation
• Iterative Optimization Yields Stapled Peptides with Superior Pharmacokinetics and Potency for Renal Fibrosis Treatment.

  2025cites this paper
• Crosstalk between ferroptosis and innate immune in diabetic kidney disease: mechanisms and therapeutic implications

  2025cites this paper
• Targeting the CCL2/CCR2 Axis in Colorectal Cancer; Immunopharmacological Perspectives and Therapeutic Strategies.

  2025cites this paper
• The multifaceted role of macrophages in kidney physiology and diseases

  2025cites this paper
• Gut-Derived Trimethylamine N-Oxide Promotes CCR2-Mediated Macrophage Infiltration in acute kidney injury.

  2024cites this paper
• Virus‐Induced Host Chemokine CCL2 in COVID‐19 Pathogenesis: Potential Prognostic Marker and Target of Anti‐Inflammatory Strategy

  2024cites this paper
• Harmonizing hope: navigating the osteoarthritis melody through the CCL2/CCR2 axis for innovative therapeutic avenues

  2024cites this paper
• Role of inflammation in the progression of diabetic kidney disease

  2024cites this paper
• The advance of single cell transcriptome to study kidney immune cells in diabetic kidney disease

  2024cites this paper
• Decoding the role of the CCL2/CCR2 axis in Alzheimer's disease and innovating therapeutic approaches: Keeping All options open.

  2024cites this paper
• Identification of immune-associated biomarkers of diabetes nephropathy tubulointerstitial injury based on machine learning: a bioinformatics multi-chip integrated analysis

  2024cites this paper
• Neuroimmune interactions in the development and chronification of migraine headache.

  2024cites this paper
• The therapeutic effect of mesenchymal stem cells in diabetic kidney disease

  2024cites this paper
• Fiery Connections: Macrophage-Mediated Inflammation, the Journey from Obesity to Type 2 Diabetes Mellitus and Diabetic Kidney Disease

  2024cites this paper
• Role of novel biomarker monocyte chemo-attractant protein-1 in early diagnosis & predicting progression of diabetic kidney disease: A comprehensive review.

  2024cites this paper
• Innate immunity champions: The diverse functions of macrophages

  2024cites this paper
• Renal macrophages and NLRP3 inflammasomes in kidney diseases and therapeutics

  2024cites this paper
• Depletion of CUL4B in macrophages ameliorates diabetic kidney disease via miR-194-5p/ITGA9 axis.

  2023cites this paper
• Inflammation in Diabetic Kidney Disease: Focus on New Therapeutic Considerations

  2023cites this paper
• Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation.

  2023cites this paper
• Single‐cell RNA‐seq with spatial transcriptomics to create an atlas of human diabetic kidney disease

  2023cites this paper
• CC chemokines family in fibrosis and aging: from mechanisms to therapy.

  2023cites this paper
• Therapeutic potential of artemisinin and its derivatives in managing kidney diseases

  2023cites this paper
• Immunological Approaches in the Treatment of Diabetic Nephropathy.

  2023cites this paper
• The dual-function chemokine receptor CCR2 drives migration and chemokine scavenging through distinct mechanisms

  2023cites this paper
• Ferroptosis: an important player in the inflammatory response in diabetic nephropathy

  2023cites this paper
• Role of MCP-1/CCR2 axis in renal fibrosis: Mechanisms and therapeutic targeting

  2023cites this paper
• FN1 and TGFBI are key biomarkers of macrophage immune injury in diabetic kidney disease

  2023cites this paper
• Cellular crosstalk of mesangial cells and tubular epithelial cells in diabetic kidney disease

  2023cites this paper
• Chemokines, molecular drivers of thromboinflammation and immunothrombosis

  2023cites this paper
• Single-cell transcriptomes reveal a molecular link between diabetic kidney and retinal lesions

  2023cites this paper
• NETosis: an emerging therapeutic target in renal diseases

  2023cites this paper
• Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5

  2023cites this paper
• Rare damaging CCR2 variants are associated with lower lifetime cardiovascular risk

  2023cites this paper
• Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms

  2023cites this paper
• Identification of a novel immune landscape signature as effective diagnostic markers related to immune cell infiltration in diabetic nephropathy

  2023cites this paper
• Transcriptional profile changes after treatment of ischemia reperfusion injury-induced kidney fibrosis with 18β-glycyrrhetinic acid

  2022cites this paper
• p53/sirtuin 1/NF-κB Signaling Axis in Chronic Inflammation and Maladaptive Kidney Repair After Cisplatin Nephrotoxicity

  2022cites this paper
• Chronic kidney disease mediates cardiac dysfunction associated with increased resident cardiac macrophages

  2022cites this paper
• Lysophosphatidic Acid Is a Proinflammatory Stimulus of Renal Tubular Epithelial Cells

  2022cites this paper
• The Roles of Adipose Tissue Macrophages in Human Disease

  2022cites this paper
• Signaling pathways of chronic kidney diseases, implications for therapeutics

  2022cites this paper
• IL-17A in diabetic kidney disease: protection or damage.

  2022cites this paper
• Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target

  2022cites this paper
• Kidney oxygenation, perfusion and blood flow in people with and without type 1 diabetes

  2022cites this paper
• Emerging drugs for the treatment of diabetic nephropathy

  2022cites this paper
• Targeting inflammation for the treatment of Diabetic Kidney Disease: a five-compartment mechanistic model

  2022cites this paper
• Mannose‐binding lectin activates the nuclear factor‐κB and renal inflammation in the progression of diabetic nephropathy

  2022cites this paper
• Epigenetics and endoplasmic reticulum in podocytopathy during diabetic nephropathy progression

  2022cites this paper
• Role of CCR2-Positive Macrophages in Pathological Ventricular Remodelling

  2022cites this paper
• Exploring molecular targets in diabetic kidney disease

  2022cites this paper
• Mechanisms of podocyte injury and implications for diabetic nephropathy

  2022cites this paper
• Targeting inflammation to treat diabetic kidney disease: the road to 2030.

  2022cites this paper
• Stem cell-derived and circulating exosomal microRNAs as new potential tools for diabetic nephropathy management

  2022cites this paper
• Pathophysiology of Diabetic Kidney Disease

  2022cites this paper
• CPAP Effect on Albuminuria Progression in Patients with Obstructive Sleep Apnea and Diabetic Kidney Disease. A Randomized Clinical Trial.

  2022cites this paper
• Cellular crosstalk of glomerular endothelial cells and podocytes in diabetic kidney disease

  2022cites this paper
• Macrophages in the kidney in health, injury and repair.

  2022cites this paper
• Novel biomarkers and therapeutic approaches for diabetic retinopathy and nephropathy: Recent progress and future perspectives

  2022cites this paper
• Role of CCL2/CCR2 axis in the pathogenesis of COVID-19 and possible Treatments: All options on the Table

  2022cites this paper
• Role of CCL2/CCR2 axis in the pathogenesis of COVID-19 and possible Treatments: All options on the Table International Immunopharmacology

  2022cites this paper
• Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases

  2022cites this paper
• Role of CCL2/CCR2 axis in the pathogenesis of COVID-19 and possible Treatments: All options on the Table

  2022cites this paper
• Diabetic kidney disease treatment: new perspectives

  2022cites this paper
• Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease

  2022cites this paper
• Renal fibrosis as a hallmark of diabetic kidney disease: potential role of targeting transforming growth factor-beta (TGF-β) and related molecules

  2022cites this paper
• Repurposing a clinically approved prescription Colquhounia root tablet to treat diabetic kidney disease via suppressing PI3K/AKT/NF-kB activation

  2022cites this paper
• GABA alleviates high glucose-induced podocyte injury through dynamically altering the expression of macrophage M1/M2-derived exosomal miR-21a-5p/miR-25-3p.

  2022cites this paper
• Diabetic nephropathy: A twisted thread to unravel.

  2021cites this paper
• Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists.

  2021cites this paper
• Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity

  2021cites this paper
• Role of Macrophages and Related Cytokines in Kidney Disease

  2021cites this paper
• Macrophage Heterogeneity in Kidney Injury and Fibrosis

  2021cites this paper
• Update on diagnosis, pathophysiology, and management of diabetic kidney disease

  2021cites this paper
• Diabetic Kidney Disease Represents a Locus of Opportunity

  2021cites this paper
• Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors

  2021cites this paper
• Purine adducts as a presumable missing link for aristolochic acid nephropathy‐related cellular energy crisis, potential anti‐fibrotic prevention and treatment

  2021cites this paper
• Serum Albumin Modifies the Effect of Peripheral Blood Monocytes on Severity of Diabetic Nephropathy in an Adult Population.

  2021cites this paper
• Advances in understanding the innate immune‐associated diabetic kidney disease

  2021cites this paper
• Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML.

  2021cites this paper
• Chemokines in cardiac fibrosis.

  2021cites this paper
• Adaptive immune cells shape obesity-associated type 2 diabetes mellitus and less prominent comorbidities

  2021cites this paper
• Novel Therapies for Kidney Disease in People with Diabetes.

  2021cites this paper
• Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?

  2021cites this paper
• FcER1: A Novel Molecule Implicated in the Progression of Human Diabetic Kidney Disease

  2021cites this paper